SEC Filing Summary: Obalon Therapeutics, Inc. (OBLN)
Business Context and Reporting Period
This Form 8-K was filed by Obalon Therapeutics, Inc. on May 17, 2019, reporting events occurring on May 15 and May 16, 2019. The Company is a Delaware corporation listed on the NASDAQ Global Market under the symbol OBLN. The filing addresses two separate notices of non-compliance with Nasdaq listing standards received from the Nasdaq Listing Qualifications Staff.
Key Financial Metrics
The filing references specific financial data from the Company's Form 10-Q for the quarter ended March 31, 2019:
- Stockholders' Equity: $6,518,000 (reported as below the $10,000,000 minimum requirement).
- Stock Price: The closing bid price was below $1.00 for the 30 consecutive business days preceding May 16, 2019.
The filing does not provide data regarding revenue, profit, cash flow, margins, or debt levels.
Material Changes and Listing Deficiencies
The Company received two distinct notices of non-compliance:
- Stockholders' Equity Deficiency (May 15, 2019): The Company failed to meet Nasdaq Listing Rule 5450(b)(1)(A) due to stockholders' equity of $6,518,000, which is below the required $10,000,000 minimum. The Company has 45 days to submit a compliance plan. If accepted, an extension of up to 180 days may be granted to regain compliance.
- Minimum Bid Price Deficiency (May 16, 2019): The Company failed to meet Nasdaq Listing Rule 5450(a)(1) as the closing bid price remained below $1.00 for 30 consecutive business days. The Company has 180 days (until November 12, 2019) to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
Outlook, Risks, and Management Commentary
Management intends to take all reasonable measures to regain compliance and remain listed on the Nasdaq. However, the filing explicitly states there can be no assurance that the Company will successfully regain compliance with either the minimum bid price or stockholders' equity requirements. Risks include:
- Potential delisting if compliance plans are rejected or if the Company fails to meet requirements within the allotted timeframes.
- Uncertainty regarding the success of any appeal to a hearings panel if Nasdaq determines a plan is insufficient.
- The possibility of transferring to the Nasdaq Capital Market if the Company satisfies those specific listing requirements.
Key Facts for Investor Verification
- Verify the Company's current stockholders' equity status and any capital raise activities intended to meet the $10 million threshold.
- Monitor the daily closing bid price to determine if the $1.00 threshold is met for 10 consecutive days before the November 12, 2019 deadline.
- Check for the submission of a formal compliance plan to Nasdaq within the 45-day window following the May 15 notice.
- Review subsequent filings for any updates on the status of the equity deficiency appeal or potential transfer to the Nasdaq Capital Market.